Detailed Information
Corrigendum to Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033)) : Efficacy + safety of palbociclib (P) in patients (pts) <= 50 y with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies (vol 41s1, pg s11, 2018)
- Authors
- Issue Date
- 2020-02
- Publisher
- Churchill Livingstone
- Citation
- Breast, Vol.49, pp.131-131
- Abstract
- © 2019 Elsevier LtdTwo of the authors names appeared incorrectly in the byline. The correct names are Anil Abraham Joy and Kathy Puyana Theall.
- ISSN
- 0960-9776
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.